CytoSeek appoints a new Vice President of Preclinical Development
Dr Kevin Brady, VP Preclinical Development
BRISTOL, England 12th November 2021. CytoSeek Ltd, a discovery-stage biotech company developing the next generation of cell therapies to treat cancer using its Artificial Membrane-Binding Protein (AMBP) technology, is excited to announce the appointment of Kevin Brady as Vice President of Preclinical Development. Kevin will be responsible for driving forward the preclinical development of CytoSeek’s pipeline of AMBPs and will have a pivotal role in setting regulatory strategy for preclinical aspects of future regulatory submissions. Kevin has over 15 years’ experience in the discovery and development of innovative therapies ranging from gene therapies to protein-based therapeutics including those pursuing oncology indications.
‘We are delighted to welcome Kevin to the CytoSeek team at this important stage of the company’s development to help us strengthen our development capabilities as our pipeline develops and we prepare for our next fundraising round ’ Dr Carolyn Porter, CEO, CytoSeek says.
Kevin is a strong scientific leader with a successful track record of developing novel biological drugs from discovery into early clinical development and joins CytoSeek having held previous roles at UCB, Roche, Bicycle Therapeutics and Pfizer. Kevin’s experience includes working on biologics in the field of solid tumours, which is the first target for CytoSeek’s AMBP technology. He has led teams in biotech companies, as well as large and mid-sized pharma companies, primarily focusing on early discovery and development solutions for a range of therapeutic modalities including gene therapy, antibodies, peptides and antisense oligonucleotides. In his previous roles he has also led development of regulatory strategies and coordinated cross-industry working groups focusing on regulatory aspect of biologics development.
'I am truly excited to join CytoSeek at this time. The scientific strength and depth of the team is impressive, and I look forward to delivering next generation cell therapies to cancer patients with this fantastic team’ Dr Kevin Brady, incoming VP Preclinical Development CytoSeek says.
END
About CytoSeek https://www.cytoseek.uk/
CytoSeek is a spin-out from the University of Bristol based on the research of Professor Adam Perriman (Professor of Bioengineering, School of Cellular and Molecular Medicine), who developed CytoSeek’s pioneering AMBP technology. The company’s genetic-modification-free technology enables the rapid addition of new functionalities to cell therapies that radically improve their performance. CytoSeek’s primary goal is to develop efficacious cell therapies for the treatment of cancers caused by solid tumours. CytoSeek closed a seed financing round in March 2021 raising £3.6M to support the development of the AMBP platform for its internal cell therapy programs and the development and out-licence of its novel AMBP technology
For further information please contact; Dr Carolyn Porter CEO; carolyn@cytoseek.uk or Dr Ben Carter COO; ben@cytoseek.uk.